Secondary sideroblastic anemia due to disease is a subtype of sideroblastic anemia that arises as a clinical manifestation of an underlying medical condition. It is characterized by the presence of ringed sideroblasts—erythroblasts with iron-laden mitochondria forming a ring around the nucleus—within the bone marrow. Unlike hereditary forms or those induced by external toxins, this specific classification (D64.2) identifies anemia resulting from systemic disorders. The most common associations are with hematologic malignancies, particularly myelodysplastic syndromes (MDS), specifically MDS with ring sideroblasts (MDS-RS). It may also occur in the context of myeloproliferative neoplasms, leukemias, or chronic inflammatory and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. The underlying disease disrupts the normal heme synthesis pathway or mitochondrial iron processing, leading to ineffective erythropoiesis, microcytic or normocytic anemia, and a risk of systemic iron overload despite the body's inability to utilize the iron for hemoglobin production.
Explicitly document the specific underlying disease process causing the sideroblastic shift to satisfy the due to disease requirement of the D64.2 code. Identification of a primary condition such as rheumatoid arthritis or a specific hematologic malignancy is required for clinical validity.
Example: A 69-year-old female with a 10-year history of Rheumatoid Arthritis (M06.9) presents with new-onset fatigue. Laboratory evaluation reveals a hemoglobin of 8.2 g/dL and an MCV of 105 fL. Bone marrow aspiration with Prussian blue staining demonstrates 18 percent ring sideroblasts. Diagnosis: Secondary sideroblastic anemia due to Rheumatoid Arthritis. The patient's anemia is a chronic manifestation of her underlying autoimmune disease and will require long-term management with erythropoiesis-stimulating agents.
Billing Focus: The documentation must link the sideroblastic anemia to the primary chronic or neoplastic disease using terms like due to, secondary to, or as a complication of. Accurate billing requires the primary disease to be coded first or concurrently.
Provide precise quantification of ring sideroblasts from the bone marrow biopsy report within the clinical note. This clinical detail supports the diagnosis and differentiates D64.2 from other myelodysplastic syndromes.
Example: Bone marrow biopsy performed on April 12 reveals hypercellular marrow with erythroid hyperplasia. Prussian blue staining identifies that 22 percent of erythroid precursors are ring sideroblasts. There is no evidence of excess blasts (less than 5 percent). Diagnosis: Secondary sideroblastic anemia due to underlying Myelomonocytic Leukemia. Hematocrit remains low at 24 percent despite Vitamin B6 supplementation.
Billing Focus: Numerical evidence of ring sideroblasts (exceeding 15 percent, or 5 percent if certain mutations are present) validates the use of a specific D64.x code over a generic anemia code.
Distinguish secondary sideroblastic anemia from drug or toxin-induced causes, as these are coded separately under D64.1. Documentation should clarify if the condition persists after the removal of potential toxins like alcohol or drugs like isoniazid.
Example: Patient with chronic lymphocytic leukemia presents with sideroblastic anemia. Review of current medications and social history confirms no exposure to isoniazid, linezolid, or excessive alcohol. Anemia is determined to be secondary to the primary neoplastic process of CLL rather than drug-induced. Diagnosis: Secondary sideroblastic anemia due to disease (CLL).
Billing Focus: Correct code selection between D64.1 (toxin/drug-induced) and D64.2 (disease-induced) is essential to avoid claim denials and ensure clinical accuracy for medical necessity.
Document iron studies including Serum Ferritin and Transferrin Saturation to demonstrate the iron-loading nature of this anemia. This documentation supports the medical necessity for iron chelation therapy if required.
Example: Patient with secondary sideroblastic anemia due to myelofibrosis. Serum ferritin is elevated at 1200 ng/mL with a transferrin saturation of 75 percent, indicating systemic iron overload. Monitoring for cardiac and hepatic iron deposition is initiated. Diagnosis: Secondary sideroblastic anemia due to disease with associated iron overload.
Billing Focus: Evidence of iron overload supports the use of additional codes like E83.110 (Hereditary hemochromatosis) or E83.118 (Other iron overload) and justifies related procedure codes for chelation.
Clarify the status of the underlying disease and the treatment plan for the anemia, including the use of pyridoxine (Vitamin B6) trials or erythropoietin therapy.
Example: 65-year-old male with secondary sideroblastic anemia due to multiple myeloma. Patient has failed a 3-month trial of high-dose Pyridoxine. Current management includes Epoetin alfa 40,000 units weekly and monitoring for transfusion dependence. The underlying myeloma remains in partial remission.
Billing Focus: Documenting the treatment plan and response validates the E/M level (e.g., 99214 or 99215) based on the management of a chronic condition with progression or treatment side effects.
Necessary to identify ring sideroblasts and confirm the diagnosis of D64.2.
The gold standard for diagnosing sideroblastic anemia, allowing for Prussian blue staining of the aspirate.
Used to identify Pappenheimer bodies or dimorphic red cell populations indicative of sideroblastic anemia.
Directly identifies the ring sideroblasts required to code D64.2.
Appropriate for the ongoing management of secondary sideroblastic anemia involving treatment adjustments and lab monitoring.
Used when the patient has severe anemia, systemic iron overload, or multiple progressing comorbidities.
The initial screening tool to identify the anemia and macrocytic/microcytic indices.
Crucial for assessing iron overload, a common complication of sideroblastic anemia.
Component of the iron panel used to differentiate types of anemia.
Used in conjunction with serum iron to evaluate iron homeostasis in sideroblastic patients.
Standard for the first hematology consultation for a patient with unexplained anemia.
Reserved for new patients presenting with severe anemia and multiple complex underlying diseases like active malignancy.